JNJ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
JNJ is a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The setup is constructive: the stock is in a mild pre-market uptick, trend indicators are bullish, analyst sentiment is improving, and the latest FDA approval for TREMFYA adds a clear near-term catalyst plus longer-term growth support. Given the user is impatient and does not want to wait for a perfect entry, this is an acceptable entry now rather than a stock to watch from the sidelines.
JNJ is trading at 230.68 pre-market, essentially flat but above the pivot at 230.588. The trend is still bullish overall because SMA 5 > SMA 20 > SMA 200, which signals a healthy uptrend. MACD histogram is positive at 0.918, though it is contracting, so momentum is positive but not accelerating strongly. RSI_6 at 53.985 is neutral, showing the stock is not overbought. Key levels are well defined: resistance at 234.269 and 236.542, support at 226.907 and 224.634. Overall, the technical picture favors a stable long-term entry, with limited sign of weakness.
["FDA approval for TREMFYA label expansion in psoriatic arthritis, a direct positive catalyst", "Improving new drug momentum highlighted by Leerink", "Multiple analysts raised price targets after the Q1 beat and guidance raise", "Bullish trend structure on the chart supports continuation", "Long-term pipeline visibility and MedTech stability"]
["Insiders are selling, and selling activity increased 159.20% over the last month", "Hedge funds are neutral with no significant buying trend", "Options volume is below average, suggesting no strong market excitement yet", "MACD momentum is positive but contracting, implying the trend is not accelerating", "Congress trading shows more sales than buys over the last 90 days"]
Financial snapshot data was not available due to an error, so I cannot assess the latest quarter in detail. However, the analyst commentary references a Q1 beat and a guidance raise, which suggests the most recent quarter was solid. The broader narrative from analysts points to improving revenue growth, strong Tremfya uptake, successful ICOTYDE adoption, and steady MedTech end-markets. The latest quarter season referenced in the data is Q1 2026.
Analyst sentiment has turned more positive recently. Leerink upgraded JNJ to Outperform with a $265 target, Guggenheim raised its target to $266 and kept Buy, Morgan Stanley raised its target to $283 and kept Overweight, RBC raised to $265 with Outperform, and TD Cowen initiated at Buy with $250. There is still some mixed conservatism from BofA at Neutral, Barclays at Equal Weight, and Stifel at Hold. Wall Street’s pro case is strong new drug momentum, pipeline visibility, and durable growth; the con case is that some firms see the stock as fairly valued and not thesis-changing enough to be aggressively bullish.
